Abstract:Objective:Secondary infection caused by high-dose immunosuppressive therapy is the most common cause of death in patients with ANCA-associated vasculitis. This study aimed to explore whether reduced-dose of immunosuppressive therapy could achieve effective remission together with less secondary infection in patients with mild to moderate ANCA-associated renal vasculitis, and to determine whether early secondary infections could accelerate the deterioration of renal function.Methods:The efficacy and safety of reduced-dose regimen and standard regimen were compared with Fisher′s precision probability test. The renal survival rate was estimated with the Kaplan-Meier method and compared with the log-rank test. Potential variates were examined by means of the multivariate Cox hazard regression model to determine the risk factors of end-stage renal disease, while the receiver operating characteristic (ROC) curve was applied to evaluate the sensitivity and specificity of the risk factors.Results:A total of 58 patients were included, with 35 patients in the standard-dose glucocorticoids group and 23 in the reduced-dose glucocorticoids group. The average age of the included patients was 62.45±12.70 years, and the baseline serum creatinine was 251.35 μmol/L. 9 patients (15.52%) developed end-stage renal disease (ESRD) within 24 months (7 from the standard regimen group and 2 from the reduced-dose regemen group, P=0.21). 10 patients developed secondary infection 3 months after treatment (9 from the standard regimen group and 1 from the reduced-dose regemen group, P=0.035). Multivariate Cox regression model analysis displayed that the baseline serum creatinine (HR 0.007, 95%CI: 2.48-39.48, P=0.014), secondary infection rate within first 3 months (HR 2.28, 95% CI: 2.14-45.27, P=0.003), and persistent hematuria for more than 6 months (HR 1.723, 95%CI: 0.043-0.738, P=0.017) were risk factors of ESRD in patients with ANCA-associated renal vasculitis.Conclusion:The regimen of initial reduced-dose immunosuppressive therapy could significantly reduce the secondary infection rate in patients with mild to moderate ANCA-associated renal vasculitis, while the efficacy was not inferior to that of the standard regimen. Patients who had secondary infection within the first 3 months of treatment were at higher risk of early progression to ESRD.

Reduced Regime of Glucocorticoids and Cyclophosphamide for Mild ANCA-Associated Renal Vasculitis May Delay Deterioration of Renal Function

Analysis of the Efficacy and Renal Prognosis of Reduced-Dose Immunosuppressive Regimen in Patients with Mild to Moderate ANCA-associated Renal Vasculitis

The impact of intravenous methylprednisolone pulses on renal survival in anti-neutrophil cytoplasmic antibody associated vasculitis with severe renal injury patients: a retrospective study

Pathological Classification and Prognosis of Renal Damage Caused by Antineutrophil Cytoplasmic Antibody Associated Vasculitis

Late Restoration of Renal Function in Patients with Severe ANCA-associated Glomerulonephritis Who Were Dialysis-Dependent at Presentation

A RETROSPECTIVE STUDY ON COMBINED TREATMENT OF CONTINUOUS AMBULATORY PERITONEAL DIALYSIS AND IMMUNOSUPPRESSIVE THERAPY OF ANCA-ASSOCIATED VASCULITIS COMPLICATING RENAL FAILURE

Predictors of Poor Prognosis in ANCA-associated Vasculitis (AAV): a Single-Center Prospective Study of Inpatients in China

Analysis of the risk factors for end‑stage renal disease and mortality in ANCA-associated vasculitis: a study from a single center of the Chinese Rheumatism Data Center

Immunoadsorption Improves Remission Rates of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Severe Kidney Involvement

Outcome and risk factors for renal involvement in patients with anti-neutrophil cytoplasmic antibody associated vasculitis

Prognosis and Risk Factors of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Patients on Maintaining Dialysis

Supplementary Material For: Immunoadsorption Improves Remission Rates of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Severe Kidney Involvement

Efficacy and Safety of Glucocorticoids Therapy for IgA Nephropathy: a Meta-Analysis of Randomized Controlled Trials.

Predictors for Outcomes in Patients with Severe ANCA-associated Glomerulonephritis Who Were Dialysis-dependent at Presentation: A Study of 89 Cases in a Single Chinese Center

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

B cell-driven reduced-dose rituximab as induction therapy for 2 patients with ANCA-associated renal vasculitis: A case series

Efficacy of protein A immunoadsorption and therapeutic plasma exchange in ANCA-associated vasculitis with severe renal involvement: a retrospective study

Renal pathologic classification and the long-term outcome in patients with ANCA associated vasculitis

Evaluation of Therapeutic Effects on ANCA-associated Vasculitis and Renal Failure

Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy

Wide variation in glucocorticoid dosing in paediatric ANCA-associated vasculitis with renal disease: a paediatric vasculitis initiative study